Overview
The primary goal of this project is to study the feasibility of a brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of human brains. The study will also allow us to compare the imaging performance of the investigator's brain-dedicated PET insert against a commercial whole-body permanently integrated PET/MRI system using a common radiopharmaceutical.
Description
This study will enroll up to 40 participants.
- 20 participants at Stanford injected with an FDA-approved PET tracer (e.g. amyloid, FDG, etc.), and
- 20 participants from Stanford who have been pre-injected with a radiopharmaceutical for a study on another PET imaging system
Eligibility
Inclusion Criteria:
- Whole body radiation dose within the last year of less than 5000 mrem
- Subjects intended for injected tracer studies (not associated with another study) must be willing/able to undergo injection of 6-12 mCi of either FDG or Neuraceq radiotracer. Both tracers are FDA approved
- Subjects will be at least 21 years of age
- Subject provides written informed consent
- Subject is deemed healthy by the PI by via self-reported questionnaire
Exclusion Criteria:
- For patients who will be receiving a tracer injection, no known allergy to the imaging agents
- Participant has a history of or current diagnosis of cancer
- Participant is pregnant or nursing
- Metallic implants (contraindicated for MRI)